Truist Financial’s Moleculin Biotech MBRX Stock Holding History

Truist Financial’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21	Closed	-$5.56K	–	2822
2025 Q3	$5.56K	Hold	21	–	–	﹤0.01%	2707
2025 Q2	$3.17K	Hold	21	–	–	﹤0.01%	2590
2025 Q1	$10.2K	Hold	21	–	–	﹤0.01%	2534
2024 Q4	$17.8K	Hold	21	–	–	﹤0.01%	2499
2024 Q3	$29.8K	Buy	+21	New	+$30.3K	﹤0.01%	2466
2021 Q4	–	Sell	-4	Closed	-$88K	–	2803
2021 Q3	$88K	Hold	4	–	–	﹤0.01%	2649
2021 Q2	$107K	Hold	4	–	–	﹤0.01%	2649
2021 Q1	$119K	Hold	4	–	–	﹤0.01%	2567
2020 Q4	$139K	Hold	4	–	–	﹤0.01%	2437
2020 Q3	$142K	Buy	4 +1	+33%	+$42.5K	﹤0.01%	2318
2020 Q2	$135K	Hold	3	–	–	﹤0.01%	2256
2020 Q1	$85K	Hold	3	–	–	﹤0.01%	2265
2019 Q4	$128K	Hold	3	–	–	﹤0.01%	2402
2019 Q3	$155K	Hold	3	–	–	﹤0.01%	765
2019 Q2	$175K	Hold	3	–	–	﹤0.01%	760
2019 Q1	$113K	Buy	3 +1	+50%	+$59.6K	﹤0.01%	757
2018 Q4	$94K	Hold	2	–	–	﹤0.01%	748
2018 Q3	$144K	Hold	2	–	–	﹤0.01%	762
2018 Q2	$161K	Hold	2	–	–	﹤0.01%	743
2018 Q1	$162K	Hold	2	–	–	﹤0.01%	741
2017 Q4	$167K	Hold	2	–	–	﹤0.01%	773
2017 Q3	$215K	Hold	2	–	–	﹤0.01%	744
2017 Q2	$168K	Buy	2 +1	+100%	+$43.5K	﹤0.01%	759
2017 Q1	$47K	Buy	+1	New	+$70K	﹤0.01%	814
2016 Q4	–	Hold	0	–	–	–	823

Other funds holding MBRX

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EFG International Zurich $5.46B AUM

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Truist Financial's MBRX Position: Q4 2025 in Review

Truist Financial sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 21 shares — an estimated $5.56K sold.

Truist Financial first reported a position in MBRX in Q1 2017 and held it in 24 quarters. The position peaked at $215K in Q3 2017. 14 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

Truist Financial reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
Truist Financial sold 21 Moleculin Biotech shares in Q4 2025, an estimated $5.56K.
Truist Financial first reported a position in Moleculin Biotech in Q1 2017 and held it in 24 quarters.
Truist Financial's Moleculin Biotech position peaked at $215K in Q3 2017.
14 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.